MedicaidCoverageMedium impact
Inhaled Nitric Oxide - MEDICAID - INDIANA (New)
Humana·IN · Pediatrics, Cardiology, Pulmonology +1 more·Pharmacy
Effective date
Mar 18, 2026
We identified it
Jun 24, 2026
Summary
Humana is implementing a new policy for inhaled nitric oxide (iNO) coverage under Indiana Medicaid, effective March 18, 2026. The policy covers iNO for specific conditions including persistent pulmonary hypertension in newborns, postoperative pulmonary hypertension in infants/children with congenital heart disease, and vasoreactivity testing in adults with pulmonary arterial hypertension.
Action Required
Before March 18, 2026: Billing team must update system to recognize new iNO coverage criteria for Indiana Medicaid members. Ensure prior authorization processes capture required documentation including gestational age ≥34 weeks for neonates, evidence of PPHN, failure of conventional therapy, absence of congenital diaphragmatic hernia, and maximum 14-day treatment duration. Update clinical documentation requirements for CPT 93463 when used for vasoreactivity testing.